Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Benjamin J BulenNickolay A KhazanovDaniel H HovelsonLaura E LambMarc MatranaMark E BurkardEddy Shih-Hsin YangWilliam Jeffery EdenfieldElizabeth C DeesAdedayo A OnitiloGary L BuchschacherAlan M MillerBenjamin M ParsonsTimothy R WassenaarJennifer M SugaRobert D SiegelWilliam IrvinSuresh G NairJennifer N SlimJamal MislehJamil KhatriGregory A MastersSachdev ThomasMalek M SafaDaniel M AndersonJonathan MowersAnna C DusenberyStephanie DreweryKomal PlouffeTravis ReederHana VakilLynnae PatriasAmanda FalzettaRyan HamiltonKat KwiatkowskiD Bryan JohnsonDaniel R RhodesScott A TomlinsPublished in: Cancer research communications (2023)
This study confirms the utility of the integrative IRS biomarker for predicting anti-PD-L1/PD-1 benefit. IRS significantly improved upon currently available biomarkers, including PD-L1 IHC, TMB, and MSI status. Additional utility for informing on chemotherapy, anti-PD-L1/PD-1, and anti-PD-L1/PD-1 plus chemotherapy treatments decisions is shown.